{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:50:54Z","timestamp":1784677854983,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2009,8,21]],"date-time":"2009-08-21T00:00:00Z","timestamp":1250812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s11095-009-9956-5","type":"journal-article","created":{"date-parts":[[2009,8,20]],"date-time":"2009-08-20T19:11:18Z","timestamp":1250795478000},"page":"2446-2453","source":"Crossref","is-referenced-by-count":43,"title":["Utility of Nanosized Microemulsion for Transdermal Delivery of Tolterodine Tartrate: Ex-Vivo Permeation and In-Vivo Pharmacokinetic Studies"],"prefix":"10.1007","volume":"26","author":[{"given":"Ahmed H.","family":"Elshafeey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany O.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen M.","family":"Fathallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,21]]},"reference":[{"key":"9956_CR1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation subcommittee of the International Continence Society. Urology. 2003;61:37\u201349.","journal-title":"Urology."},{"key":"9956_CR2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327\u201336.","journal-title":"World J Urol"},{"key":"9956_CR3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474\u20139.","journal-title":"J Urol"},{"key":"9956_CR4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1464-410X.2005.05889.x","volume":"97","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Kopp Z. Impact of overactive bladder symptoms on employment, social interactions and emotional wellbeing in six European countries. BJU Int. 2006;97:96\u2013100.","journal-title":"BJU Int."},{"key":"9956_CR5","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.urology.2006.03.006","volume":"68","author":"SA Kaplan","year":"2006","unstructured":"Kaplan SA, Roehrborn CG, Dmochowski R. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006;68:328\u201332.","journal-title":"Urology."},{"key":"9956_CR6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1524-4733.2005.00041.x","volume":"8","author":"YF Yu","year":"2005","unstructured":"Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder\/urinary incontinence in the California Medicaid Program. Value Health. 2005;8:495\u2013505.","journal-title":"Value Health."},{"key":"9956_CR7","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0022-5347(05)66326-4","volume":"165","author":"J Malone-Lee","year":"2001","unstructured":"Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine superior tolerability and comparable efficacy to oxybutynin in individuals 50\u00a0years old or older with overactive bladder: a randomized controlled trial. J Urol. 2001;165:1452\u20136.","journal-title":"J Urol."},{"issue":"7","key":"9956_CR8","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1517\/13543784.8.7.1073","volume":"8","author":"SR Serels","year":"1999","unstructured":"Serels SR, Appell RA. Tolterodine: a new antimuscarinic agent for the treatment of the overactive bladder. Expert Opin Investig Drugs. 1999;8(7):1073\u20138.","journal-title":"Expert Opin Investig Drugs."},{"issue":"7","key":"9956_CR9","first-page":"287","volume":"35","author":"N Brynne","year":"1997","unstructured":"Brynne N, Stahl MM, Hallen B, Edlund PO, Palmer L, Hoglund P, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther. 1997;35(7):287\u201395.","journal-title":"Int J Clin Pharmacol Ther."},{"key":"9956_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.12.005","volume":"332","author":"MMA Elsayed","year":"2007","unstructured":"Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int. J. Pharm. 2007;332:1\u201316.","journal-title":"Int. J. Pharm."},{"key":"9956_CR11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cis.2006.05.014","volume":"123\u2013126","author":"A Kogan","year":"2006","unstructured":"Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv. Colloid Interface Sci. 2006;123\u2013126:369\u2013385.","journal-title":"Adv. Colloid Interface Sci."},{"issue":"5","key":"9956_CR12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1023\/A:1011068907416","volume":"18","author":"M Kreilgaard","year":"2001","unstructured":"Kreilgaard M, Kemme MJ, Burggraaf J, Schoemaker RC, Cohen AF. Influence of a microemulsion vehicle on cutaneous bioequivalence of a lipophilic model drug assessed by microdialysis and pharmacodynamics. Pharm Res. 2001;18(5):593\u20139.","journal-title":"Pharm Res."},{"issue":"1\u20132","key":"9956_CR13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijpharm.2005.12.019","volume":"311","author":"AC Sintov","year":"2006","unstructured":"Sintov AC, Botner S. Transdermal drug delivery using microemulsion and aqueous systems: influence of skin storage conditions on the in vitro permeability of diclofenac from aqueous vehicle systems. Int J Pharm. 2006;311(1\u20132):55\u201362.","journal-title":"Int J Pharm."},{"issue":"1\u20132","key":"9956_CR14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0378-5173(03)00063-2","volume":"256","author":"P Spiclin","year":"2003","unstructured":"Spiclin P, Homar M, Zupancic-Valant A, Gasperlin M. Sodium ascorbyl phosphate in topical microemulsions. Int J Pharm. 2003;256(1\u20132):65\u201373.","journal-title":"Int J Pharm."},{"issue":"4","key":"9956_CR15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF03189968","volume":"16","author":"VP Shah","year":"1991","unstructured":"Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet. 1991;16(4):249\u201355.","journal-title":"Conference report. Eur J Drug Metab Pharmacokinet."},{"issue":"1\u20132","key":"9956_CR16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0378-5173(00)00674-8","volume":"215","author":"MJ Alvarez-Figueroa","year":"2001","unstructured":"Alvarez-Figueroa MJ, Blanco-Mendez J. Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int. J. Pharm. 2001;215(1\u20132):57\u201365.","journal-title":"Int. J. Pharm."},{"issue":"11","key":"9956_CR17","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.addr.2007.07.004","volume":"59","author":"B Godin","year":"2007","unstructured":"Godin B, Touitou E. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev. 2007;59(11):1152\u201361.","journal-title":"Adv Drug Deliv Rev"},{"key":"9956_CR18","unstructured":"''Declaration of Helsinki.'' As amended by the 52nd World Medical Assembly (WMA). World Medical Association, Edinburgh, Scotland, October 2000."},{"key":"9956_CR19","unstructured":"International conference of harmonization of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline. Guidelines for good clinical practice. May 1996."},{"key":"9956_CR20","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1023\/A:1015845632280","volume":"8","author":"B Ongpipattanakul","year":"1991","unstructured":"Ongpipattanakul B, Burnette RR, Potts RO, Francoeur ML. Evidence that oleic acid exists in a separate phase within stratum corneum lipids. Pharm. Res. 1991;8:350\u2013354.","journal-title":"Pharm. Res."},{"key":"9956_CR21","first-page":"1","volume":"184","author":"J Hadgraft","year":"1999","unstructured":"Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery Int. J. of Pharm. 1999;184:1\u20136.","journal-title":"J. of Pharm."},{"key":"9956_CR22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0378-5173(95)04348-9","volume":"132","author":"P Mayorga","year":"1996","unstructured":"Mayorga P, Puisieux F, Couarraze G. Formulation study of a transdermal delivery system of primaquine. Int. J. Pharm. 1996;132:71\u201379.","journal-title":"Int. J. Pharm."},{"issue":"5","key":"9956_CR23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1248\/bpb.31.1045","volume":"31","author":"XS Zheng","year":"2008","unstructured":"Zheng XS, Duan CZ, Xiao ZD, Yao BA. Transdermal delivery of praziquantel: effects of solvents on permeation across rabbit skin. Biol Pharm Bull. 2008;31(5):1045\u20138.","journal-title":"Biol Pharm Bull."},{"issue":"16","key":"9956_CR24","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1359-6446(04)03180-0","volume":"9","author":"BJ Thomas","year":"2004","unstructured":"Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov. Today. 2004;9(16):697\u2013703.","journal-title":"The transdermal revolution. Drug Discov. Today."},{"issue":"3","key":"9956_CR25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1208\/s12249-008-9107-z","volume":"9","author":"A Fini","year":"2008","unstructured":"Fini A, Bergamante V, Ceschel GC, Ronchi C, De Moraes CA. Control of transdermal permeation of hydrocortisone acetate from hydrophilic and lipophilic formulations. AAPS PharmSciTech. 2008;9(3):762\u20138.","journal-title":"AAPS PharmSciTech."},{"key":"9956_CR26","doi-asserted-by":"crossref","unstructured":"Menon G.K. New insights into skin structure: scratching the surface. Adv Drug Deliv Rev. 54 (1): S3\u201317(2002).","DOI":"10.1016\/S0169-409X(02)00121-7"},{"issue":"13","key":"9956_CR27","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/03639049209040848","volume":"18","author":"K Klamerus","year":"1992","unstructured":"Klamerus K, Lee G. Effects of some hydrophilic permeation enhancers on the absorption of bepridil through excised human skin. Drug Dev. and Ind. Pharmacy. 1992;18(13):1411\u20131422.","journal-title":"Drug Dev. and Ind. Pharmacy."},{"key":"9956_CR28","doi-asserted-by":"crossref","unstructured":"M. Kreilgaard, E.J. Pedersen, J.W. Jaroszewski. NMR. characterisation and transdermal drug delivery potential of microemulsion systems. J. Control Rel. 69:421\u2013433 (2000).","DOI":"10.1016\/S0168-3659(00)00325-4"},{"key":"9956_CR29","unstructured":"H. E. J. Hofland, J. A. Bouwstra, F. Spies, G. Gooris, H. E. Junginger. Interaction between liposomes and human skin in vitro: Poster presentation. Conference: Liposomes in Drug Delivery 21\u00a0years On, London, 12\u201315 (1990)."},{"key":"9956_CR30","unstructured":"N. Weiner, K. Egbaria. Topical application of liposomal systems: Poster presentation. Conference: Liposomes in Drug Delivery 21\u00a0years On, London, 12\u201315 (1990)."},{"issue":"3","key":"9956_CR31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF02980072","volume":"27","author":"JH Kweon","year":"2004","unstructured":"Kweon JH, Chi SC, Park Transdermal ES. delivery of diclofenac using microemulsions. Arch Pharm Res. 2004;27(3):351\u20136.","journal-title":"Arch Pharm Res."},{"key":"9956_CR32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0939-6411(96)00016-1","volume":"43","author":"MB Delgado-Charro","year":"1997","unstructured":"Delgado-Charro MB, Iglesias-Vilas G, Blanco-Mendez J, Lopez-Quintela MA, Marty JP, Guy RH. Delivery of a hydrophilic solute through the skin from novel microemulsion systems. Eur. J. Pharm. Biopharm. 1997;43:37\u201342.","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"9956_CR33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003088-200140030-00006","volume":"40","author":"B Olsson","year":"2001","unstructured":"Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet. 2001;40(3):227\u201335.","journal-title":"Clin Pharmacokinet."},{"key":"9956_CR34","doi-asserted-by":"crossref","unstructured":"Guay D.R.P. Clinical Pharmacokinetics of Drugs Used to Treat Urge Incontinence Clin Pharmacokinet. 42(14): 1243\u20131285 (2003).","DOI":"10.2165\/00003088-200342140-00004"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-009-9956-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-009-9956-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-009-9956-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T15:58:49Z","timestamp":1590076729000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-009-9956-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,21]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["9956"],"URL":"https:\/\/doi.org\/10.1007\/s11095-009-9956-5","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,21]]}}}